Lv57
960 积分 2023-11-06 加入
The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma
22天前
已完结
The evolving landscape of antibody-drug conjugates in ovarian cancer: new drugs for a new era
2个月前
已完结
The Trop-2-targeting antibody drug conjugate DB-1305 has higher antitumor activity and a potentially better safety profile compared with DS-1062
2个月前
已完结
Ocular toxicities of fibroblast growth factor receptor inhibitors: A review
4个月前
已完结
Emerging treatment approaches for triple-negative breast cancer
4个月前
已完结
Trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment
4个月前
已完结
The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan
4个月前
已完结
Antibody-Drug Conjugates in Breast Cancer: What Is Beyond HER2?
4个月前
已完结
Development of Antibody-Drug Conjugates: Future Perspective Towards Solid Tumor Treatment
5个月前
已完结
A phase I study to evaluate the safety, tolerability, and pharmacokinetics of MSB0254 in Chinese patients with solid tumors
5个月前
已完结
皖公网安备34019202002308
